GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study

CompletedOBSERVATIONAL
Enrollment

124

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

October 6, 2023

Study Completion Date

October 6, 2023

Conditions
Vascular Stent-Graft Stenosis
Interventions
DEVICE

GORE® VIABAHN® Stent Graft

On Day 1, participants will receive the GORE® VIABAHN® Stent Graft.

Trial Locations (17)

454-0933

Kaikoukai Central Clinic, Nagoya

464-0850

Nagoya Vascular Access Clinic, Nagoya

790-8524

Matsuyama Red Cross Hospital, Matsuyama

660-8511

Kansai Rosai Hospital, Amagasaki

920-0007

Kanazawa Cardiovascular Hospital, Kanazawa

220-0011

Yokohama Dai-ichi Hospital, Yokohama

861-8520

Japanese Red Cross Kumamoto Hospital, Higashi

350-8550

Saitama Medical Center, Kawagoe

420-8527

Shizuoka General Hospital, Aoi

410-0043

Bouseidai1 Clinic, Numazu

102-0072

Haruguchi Vascular Access Clinic, Chiyoda City

180-0004

Kichijoji Asahi Hospital, Musashino

171-0031

Vascular Access Clinic Mejiro, Toshima City

409-3898

University of Yamanashi Hospital, Chūō

812-0046

Fukuoka City Hospital, Fukuoka

Unknown

Ikeda Vascular Access, Dialysis and Internal Medicine Clinic, Fukuoka

530-6012

Osaka Vascular Access Temma Nakamura Clinic, Osaka

All Listed Sponsors
lead

W.L.Gore & Associates

INDUSTRY

NCT04429243 - GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study | Biotech Hunter | Biotech Hunter